I'm LongbridgeAI, I can summarize articles.CMB International Securities analyst Jill Wu reaffirmed a Buy rating on Kelun-Biotech, raising the target price from HK$507.11 to HK$642.29. The upgrade reflects strong momentum in sac-TMT commercialization, robust H1 revenue growth, and successful Phase 3 trial results across multiple tumor types. Increased confidence in global trials and MSD-led programs drove the DCF-derived valuation increase.
CMB International Securities analyst Jill Wu maintained a Buy rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H today and set a price target of HK$642.29.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jill Wu has given his Buy rating due to a combination of factors tied to Kelun-Biotech’s strong operating and clinical momentum. The company delivered faster-than-expected commercialization of sac-TMT in China, with robust first-half revenue growth, a profitable swing supported by NRDL-driven uptake, and additional indications likely entering reimbursement later this year to sustain volume expansion.
Jill Wu’s rating is based on sac-TMT’s increasingly validated global and domestic profile, including multiple successful Phase 3 results that support blockbuster potential and broaden its use across NSCLC, TNBC and other tumors. Reflecting higher confidence in these global trials and MSD-led development and combination programs, she lifted her DCF-derived target price from HK$507.11 to HK$642.29, reinforcing a favorable risk-reward and justifying the Buy recommendation.